Haematology 4: Myeloproliferative Disorders Flashcards Preview

Year 5 path SW > Haematology 4: Myeloproliferative Disorders > Flashcards

Flashcards in Haematology 4: Myeloproliferative Disorders Deck (30)
Loading flashcards...
1
Q

What are the main differences between myeloproliferative and myelodysplastic disorders ?

A

Myelodysplastic syndromes have ineffective differentiation whereas in myeloproliferative disorders the cells are normal and fully differentiated.

2
Q

Give 4 examples of chronic myeloproliferative disorders ?

A
Polycythaemia rubra Vera 
Essential thropmbocythaemia 
Idiopathic myelofibrosis
Idiopathic erythrocytosis
chronic granulocytic leukaemia
3
Q

List 4 signs/symptoms of Polycythaemia rubra Vera ?

A

Aquagenic pruritus- itch after having a warm bath
Gout
Engorged retinal veins
Erythromelalgia- Red painful extremities

4
Q

What levels would you expect in someone with Polycythaemia rubra Vera ?:

Hb :Low/High
Hct :Low/High
MCV: Low/High
EPO: Low/High

A

Hb: High
Hct: High
MCV: High
EPO: low (suppressed because of negative feedback)

5
Q

How is Polycythaemia rubra Vera diagnosed ?

A

Bone marrow biopsy- Increased cellularity, low EPO, Reticulin fibrosis

JAK2 V617F mutation is diagnostic

6
Q

What is pseudo polycythaemia ?

A

Reduced plasma volume in presence of a normal Hb conc.

7
Q

What causes Polycythaemia where EPO is raised ?

A

Hypoxia- High altitude
Renal disease
tumours

8
Q

What are the signs of Essential Thrombocythaemia ?

A

High platelet count
CVA
DVT/PE
Splenomegaly

9
Q

What are the signs of Chronic idiopathic myelofibrosis ?

A

FLAWS
anaemia
Thrombocytosis
Hepatosplenomegaly (massive, sites for extra medullary haematopoeisis)

10
Q

What is the characteristic finding of bone marrow aspiration in Chronic idiopathic myelofibrosis

A

Dry tap

Because of the fibrosis nothing comes out

11
Q

what two things are important in the control of haemopoiesis

A
growth factors (EPO)
receptors eg tyrosine kinase
12
Q

which kinases are important in myeloproliferative neoplasms

A
BCR-ABL kinases (feature of CML)
Janus KInases (JAK2)
13
Q

describe the JAK signalling pathway

A

growth factors binding to receptors leads to activation of JAK
leads to activation of STAT pathway
JAK2 implicated in myeloid cells
STAT TF moves to the nucleus and causes transcription of genes associated with cell g+p
mutation that activates JAK constitutively means that activation of this pw not dependent on growth factor cytokines

14
Q

describe BCR-ABL negative myeloproliferative disorders

A

overproduction of one or more mature myeloid cellular elements of the blood
increased fibrosis in the BM
some cases progress to acute leukaemia
spontaneous colonies with or without EPT/TPO

15
Q

clinical presentations of myeloproliferative disorders

A

thrombosis (arterial)
splenomegaly
haemorrhage

16
Q

difference between myeloproliferation, myelodysplasia and leukaemia

A
myeloproliferation = proliferation + full differentiation 
myelodysplasia = ineffective proliferation and differentiation 
leukaemia = proloferation and no/little differentiation
17
Q

what is polycythaemia vera

A

increased production of RBC (high Hb and HCT)
independent of mechanisms that regulate haemopoiesis (EPO)
compensatory increase in plasma volume
accompanied by increase in platelets or granulocytic cells or both
mean age 60

18
Q

clinical presentation of polycythaemia vera

A
incidental on blood screen 
hyperviscocity symptoms - headaches, visual dist, fatigue, dyspnoea
increased histamine release - aquagenic pruritus, peptic ulceration (can cause iron def)
variable splenomegaly 
plethora
erythromelalgia 
thrombosis 
retinal vein encorgement 
gout
19
Q

investigations for polythemia vera

A
high Hb 
high HCT 
high MCV 
high plasma volume 
high platelets
no circulating immature cells 
low EPO
JAK 2V16F mutation 
BM biopsy - increased cellularity, reticulin fibrosis and megakaryocyte abnormalities
20
Q

diagnostic test for PV

A

JAK2 V617F mutation
positive = PV (exon 14) or eryhtrocytosis (exon 12)
negaive = pseudopolycthaemia or true polycythaemia secondary to EPO/familial

21
Q

how is polycythaemia vera treated

A

reduce viscosity and keep HCT<45%
venesection
cytoreductive therapy
aspirin

22
Q

features of idiopathic erythrocytosis

A
isolated erythrocytosis
low EPO
treated with venesection only 
absence of JAK2 V617F mutation 
some cases have a mutation in exon 12 of JAK2 
no adverse prognosis if Hct maintained
23
Q

what is essential thrombocythaemia

A

involves megakaryocyte lineage
incidental finding in 50%
thrombosis - CVA, gangrene, TIA, DVT, OE
bleeding - mucous membranes and cutaneous
minor - headaches, dizziness, visual dist
splenomagely is modest

24
Q

diagnosis of essential thrombocythaemia

A
platelets consistently > 600x10 9
megakaryocyte abnormalities
JAK 2 V617F mutation (in 50%)
splenomegaly mild
normal/slightly increased BM cellularity
25
Q

treatment for essential thrombocytaemia

A

aspirin
anagrelide
HYDROXYCARBAMIDE (main tx) - antimetabolite
alpha interferon

26
Q

what is chronic idiopathic myelofibrosis

A

clonal myeloproliferative disease with proliferation of megakaryocytes and granulocytes, associated with reactive BM fibrosis and extramedullary haemopoiesis
age >60

27
Q

presentation of chronic idiopathic myelofibrosis

A
incidental 
cytopaenias
thrombocytosis
splenomegaly (may be massive)
hepatomegaly 
hypermetabolic state - wt loss, fatigue, night sweats, hyperuricemia
28
Q

what are the stages of myelofibrosis

A

pre-fibrotic - mild blood changes, hypercellular marrrow

fibrotic - splenomegaly, blood changes, dry tap

29
Q

haematological findings of CIM

A

leucoerythroblastic picture
tear drop poikilocytes
giant platelets
circulating megakaryocytes

liver + spleen - extramedullary haemopoiesis

BM - dry tap, trephine biopsy (increased reticulin or collagen fibrosis)

30
Q

treatment for CIM

A
anaemia - transfusions
platelet transfusion
cytoreductive therapy - HYDROXYCARBAMIDE (may worsen the anaemia)
THALIDOMIDE 
BM transplant

Decks in Year 5 path SW Class (106):